If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Four sizeable groups of people are referred to as national minorities because their ancestors have lived in their respective regions for centuries: There is a Danish minority in the northernmost state of Schleswig-Holstein; the Sorbs, a Slavic population, are in the Lusatia region of Saxony and Brandenburg; the Roma and Sinti live throughout the country; and the Frisians are concentrated in Schleswig-Holstein's western coast and in the north-western part of Lower Saxony. Germany is a major destination for immigrants, ranking second in the world after the United States. In 2015, following the 2015 refugee crisis, the Population Division of the United Nations Department of Economic and Social Affairs listed Germany as host to the second-highest number of international migrants worldwide, about 5% or 12 million of all 244 million migrants. Refugee crises have resulted in substantial population increases; for example, the major influx of Ukrainian immigrants following the 2022 Russian invasion of Ukraine, whereby over 1.06 million refugees from Ukraine were recorded in Germany as of April 2023. In 2019, Germany ranked seventh among EU countries in terms of the percentage of migrants in the country's population, at 13.1%. In 2022, there were 23.8 million people—28.7 percent of the total population—who had a migration background. Germany has over 2,000 cities and towns, and 11 officially recognised metropolitan regions. The country's most populous city is Berlin, and its largest urban area is the Ruhr.
=== Similar diseases with overlapping symptoms === Bullous Pemphigoid, Cicatricial Pemphigoid, Drug Eruptions. Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Erythema Multiforme, Lichen Planus, pemphigus vulgaris, Stevens–Johnson syndrome and toxic epidermal necrolysis. PNP is most commonly mistaken for pemphigus vulgaris, due to the extreme similarities of the lesions that develop. However, the difference lies in the specificity of the autoreactive antibodies in each case.
== Skin == The stratum corneum – the outermost layer of the epidermis – is composed of terminally differentiated and enucleated corneocytes within a lipid matrix. Together with cholesterol and ceramides, free fatty acids form a water-impermeable barrier that prevents evaporative water loss. Generally, the epidermal lipid matrix is composed of an equimolar mixture of ceramides (about 50% by weight), cholesterol (25%), and free fatty acids (15%). Saturated fatty acids 16 and 18 carbons in length are the dominant types in the epidermis, while unsaturated fatty acids and saturated fatty acids of various other lengths are also present. The relative abundance of the different fatty acids in the epidermis is dependent on the body site the skin is covering. There are also characteristic epidermal fatty acid alterations that occur in psoriasis, atopic dermatitis, and other inflammatory conditions.
A rotary evaporator (rotovap) is a device used in chemical laboratories for the efficient and gentle removal of solvents from samples by evaporation. When referenced in the chemistry research literature, description of the use of this technique and equipment may include the phrase "rotary evaporator", though use is often rather signaled by other language (e.g., "the sample was evaporated under reduced pressure"). Rotary evaporators are also used in molecular cooking for the preparation of distillates and extracts. A simple rotary evaporator system was invented by Lyman C. Craig. It was first commercialized by the Swiss company Büchi in 1957. The device separates substances with different boiling points, and greatly simplifies work in chemistry laboratories. In research the most common size accommodates round-bottom flasks of a few liters, whereas large scale (20- to 50-liter) versions are used in pilot plants in commercial chemical operations.
Sources: en.wikipedia.org
=== Extracts === Products stating various E. longifolia extract ratios of 1:50, 1:100, and 1:200 are common on the market. However, extracts based on this ratio system are often misleading and hard to verify. Scientific research done on herbal products in general indicates that in many cases the content of bioactive constituents varies between products. Another option is for extraction techniques to use standardization methods to monitor the bioactive content and quality of the extract against standardization markers. Among standardization markers that have been used for E. longifolia are eurycomanone, total protein, total polysaccharide and glycosaponin, which have been recommended in a technical guideline developed by the Scientific and Industrial Research Institute of Malaysia.
=== Aversion therapy === Aversion therapy in alcoholism had its roots in Russia in the early 1930s, with early papers by Pavlov, Galant and Sluchevsky and Friken, and would remain a strain in the Soviet treatment of alcoholism well into the 1980s. In the US a particularly notable devotee was Dr Voegtlin, who attempted aversion therapy using apomorphine in the mid to late 1930s. However, he found apomorphine less able to induce negative feelings in his subjects than the stronger and more unpleasant emetic emetine.
Theft of prisoner's possessions by soldiers, dirty, cramped quarters and bad food, prisoners forced into uncomfortable positions for prolonged periods of time, extreme exposure to the elements, and excessive jailings of people based on the paid testimony of individual informants were reported. 55-year-old cafe owner Mahmoud Khodair, who was arrested and held for six months before being released in early March without ever knowing what he was charged with, stated, "It was just like hell", and "Nothing has changed since Saddam. Before, the Mukhabarat [secret police] would take us away, and at least they wouldn't blow down the door. Now, some informant fingers you and gets $100 even if you're innocent." During April 2004 the media started to report on the abuse. The journalist Seymour Hersh (who was awarded the Pulitzer Prize for his disclosure of the Vietnam War tragedy at the hamlet of My Lai) published a series of articles in The New Yorker with photo coverage of U.S. soldiers abusing prisoners in the Abu Ghraib prison on 2004-04-30. In an interview with Dan Rather, the deputy director of operations for the US-led coalition, Brig. Gen. Mark Kimmitt, stated "We're appalled. These are our fellow soldiers. These are the people we work with every day. They represent us. They wear the same uniform as us, and they let their fellow soldiers down.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.